RhoVac submits application for the start of clinical phase IIb study with the drug candidate RV001

On April 4, 2019 RhoVac AB ("RhoVac") reported, that the company has submitted the application for clinical trial (CTA, Clinical Trial Application) to the Danish Medicines Agency (Laegemiddelstyrelsen) and to the Scientific Ethics Committee (Press release, RhoVac, APR 4, 2019, View Source [SID1234535005]). The application is for a permit to start a clinical phase IIb study with the drug candidate RV001 in prostate cancer patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The drug candidate RV001 is targeting early metastasis in cancer patients. The proposed study focuses on prostate cancer patients, who have completed primary treatment (prostatectomy or radiation therapy) and show increasing level of prostate cancer marker PSA. It is a randomized, placebo-controlled and double-blind study. The primary goal of the study, designated RhoVac-002 ("BRAVAC"), is to evaluate whether treatment with the drug candidate RV001 can reduce PSA progression compared to the control group (placebo group).

Application for the forthcoming phase IIb study has been submitted to the Danish Medicines Agency and to the Scientific Ethics Committee. Assuming approval from these authorities, the study is expected to be initiated, in accordance with the communicated schedule, at mid-2019.

CEO Anders Ljungqvist comments:
-The very extensive work on preparing and completing the documentation and the application of the clinical Phase IIb study has now been completed. It has been a productive and close collaboration between employees and partners. It is with pleasure that we are now looking forward to the next clinical development phase of the company’s drug candidate RV001. We have completed the first clinical phase and have documented that RV001 is well tolerated by the patients with a very good safety profile. In addition, we have documented that treatment with the drug candidate provides a very significant and robust immunological response – a response that is also significant 6 months after the end of treatment. Based on this positive background, we look forward to the next coming clinical trial of the drug candidate RV001.

For more information. Please contact:
Anders Ljungqvist – CEO, RhoVac AB
Telephone: +45 4083 2365
E-mail: [email protected]

This information is such that RhoVac AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 4th April 2019.



NANOBIOTIX ANNOUNCES FIRST EVER RADIOENHANCER TO RECEIVE EUROPEAN MARKET APPROVAL

On April 4, 2019 NANOBIOTIX (Euronext : NANO – ISIN : FR0011341205), a clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, reported that Hensify (NBTXR3) has obtained a CE mark for the treatment of locally-advanced soft tissue sarcoma ("STS") (Press release, Nanobiotix, APR 4, 2019, View Source [SID1234535003]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Hensify is the brand name for NBTXR3 as approved for the treatment of locally-advanced STS. Hensify is a first-in-class product introducing a new, physical mechanism of action. This innovative product was designed by Nanobiotix to physically destroy tumors and activate the immune system for both local control and systemic disease treatment when combined with radiation therapy. In addition to Hensify, NBTXR3 is currently under evaluation in various other indications such as lung cancer, head and neck cancers, liver cancer, and prostate cancer.

Hensify is an aqueous suspension of crystalline hafnium oxide (HfO2) nanoparticles designed for injection directly into a tumor prior to a patient’s first standard radiotherapy treatment. When exposed to ionizing radiation, Hensify amplifies the localized, intratumor killing effect of that radiation. The dose of X-ray delivered to the tumor is magnified, whilst the dose passing through healthy tissues remains unchanged. Hensify requires a single administration and will fit into current worldwide standards of radiation care.

STSs are rare cancers that develop in different types of soft tissues including fat, muscles, joint structures and blood vessels. Radiotherapy followed by surgery is part of the typical treatment regimen for STS patients in Europe. The Act.In.Sarc phase II/III trial was a prospective, randomized (1:1), multinational, open label and active controlled two armed trial of 180 adult patients with locally advanced STS of the extremity or trunk wall. The objective of the trial was to evaluate the pre-operative efficacy and the safety of Hensify activated by radiotherapy compared to the standard of care (radiotherapy alone).

The positive Act.In.Sarc study results were presented at the 2018 ASTRO and ESMO (Free ESMO Whitepaper) Annual Congresses. The trial achieved its primary endpoint with a pathological complete response (<5% viable cancer cells) rate of 16.1% in the Hensify arm compared to 7.9% in the control arm (p=0.0448). In addition, in the subgroup of patients with a more aggressive disease (histologic grade 2 and 3), a pathological complete response was achieved in four times as many patients in the Hensify arm as in the control arm (17.1% compared 3.9%).

Similar safety profiles were observed in the Hensify arm and the radiation therapy alone control arm. Hensify did not impair the patients’ ability to receive the planned dose of radiotherapy and the radiotherapy safety profile was similar in both arms, including the rate of postsurgical wound complications. Hensify was associated with grade 3-4 acute immune reactions which were manageable and of short duration. Further, Hensify showed a good local tolerance in the trial and did not have any impact on the severity or incidence of radiotherapy-related adverse events. 2 Post-approval trials are planned across Europe and discussions on next steps regarding potential further development are ongoing.

About Hensify (NBTXR3)
NBTXR3 is a first-in-class product designed to destroy, when activated by radiotherapy: • tumors through physical cell death • metastasis due to immunogenic cell death leading to activation of the immune system.

NBTXR3 has a high degree of biocompatibility, requires one single administration before the first radiotherapy treatment session, and has the ability to fit into current worldwide standards of radiation care. The physical mode of action of NBTXR3 makes it applicable across solid tumors such as lung, prostate, liver, glioblastoma, and breast cancers.

NBTXR3 is actively being evaluated in head and neck cancer with locally advanced squamous cell carcinoma of the oral cavity or oropharynx in elderly and frail patients unable to receive chemotherapy or cetuximab with very limited therapeutic options. Promising results have been observed in the phase I/II trial regarding the local control of the tumors. In the United States, based on the discussions with the Food and Drug Administration that occurred in the first half of 2019, the Company plans to begin the clinical trial authorization process in the second half of 2019 and commence a phase II/III clinical trial in locally advanced head and neck cancers.

Nanobiotix is also running an Immuno-Oncology development program. In the United States, the Company received approval from the Food and Drug Administration to launch a clinical trial of NBTXR3 activated by radiotherapy in combination with antiPD-1 antibodies in lung, and head and neck cancer patients (head and neck squamous cell carcinoma and non-small cell lung cancer).

The other ongoing NBTXR3 trials are treating patients with liver cancers (hepatocellular carcinoma and liver metastasis), locally advanced or unresectable rectal cancer in combination with chemotherapy, head and neck cancer in combination with concurrent chemotherapy, and prostate adenocarcinoma.

Further, the company has a large-scale, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center (9 new phase I/II clinical trials in the United States) to evaluate NBTXR3 across head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers.

Janssen Announces Investigational CAR-T Therapy JNJ-68284528 Granted PRIME Designation by the European Medicines Agency

On April 4, 2019 The Janssen Pharmaceutical Companies of Johnson & Johnson reported that the European Medicines Agency (EMA) has granted a PRIME (PRIority MEdicines) designation for the company’s investigational B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy, JNJ-68284528 (JNJ-4528) (Press release, Johnson & Johnson, APR 4, 2019, View Source [SID1234535000]). PRIME offers enhanced interaction and early dialogue to optimise development plans and speed up evaluation of cutting-edge, scientific advances that target a high unmet medical need.1

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The PRIME designation of this novel BCMA CAR-T therapy highlights the value of regulatory innovation in the European Union," said Sjaak Bot, Vice President, Head EMEA Regulatory Affairs at Janssen Biologics B.V. "We hope to bring this important advance to patients as quickly as possible and this PRIME designation, the first for Janssen, marks an important milestone towards potential market approval."

The PRIME designation is based on results from the Phase 1/2 LEGEND-2 study (NCT03090659) evaluating LCAR-B38M CAR-T cells, sponsored by Nanjing Legend Biotech Co.,2 and the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating JNJ-4528, sponsored by Janssen and being conducted in collaboration with Legend Biotech USA Inc.3 Results from the LEGEND-2 study were presented at the American Society of Hematology (ASH) (Free ASH Whitepaper) 2018 annual meeting.4 Results from the CARTITUDE-1 study will be presented in the future.

"CAR-T therapy is an exciting therapeutic platform that harnesses the patient’s immune system to attack tumour cells," said Sen Zhuang, M.D., Ph.D., Vice President, Oncology Clinical Development, Janssen Research & Development, LLC. "We continue to advance this novel BCMA targeted CAR-T therapy through clinical studies globally as we strive to bring it to the patients with multiple myeloma around the world."

JNJ-4528 is currently being investigated for the treatment of patients with multiple myeloma who have received at least three prior regimens, including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody, and have documented disease progression within 12 months of starting the most recent therapy, or are double refractory to an IMiD and PI.3 These patients have few available treatment options and are often faced with poor outcomes.5

In December 2017, Janssen entered into a worldwide collaboration and licence agreement with Legend Biotech to jointly develop and commercialise LCAR-B38M in multiple myeloma.6 In China, the Phase 2 CARTIFAN-1 confirmatory trial (NCT03758417), sponsored by Nanjing Legend Biotech Co. Ltd. and registered with the Center for Drug Evaluation (CTR20181007), is actively recruiting to further evaluate LCAR-B38M in patients with advanced relapsed or refractory multiple myeloma.7

About LEGEND-2

LEGEND-2 (NCT03090659) is an ongoing single-arm, open-label Phase 1/2 study being conducted at four participating hospitals in China evaluating the efficacy and safety of LCAR-B38M for the treatment of relapsed or refractory multiple myeloma.2

About CAR-T and BCMA

CAR T-cells are an innovative approach to eradicating cancer cells by harnessing the power of a patient’s own immune system. BCMA is a protein that is highly expressed on myeloma cells.8 By targeting BCMA via this approach, CAR-T therapies may have the potential to redefine treatment for multiple myeloma.

About Multiple Myeloma

Multiple myeloma is an incurable blood cancer that starts in the bone marrow and is characterised by an excessive proliferation of plasma cells.9 In Europe, more than 48,200 people were diagnosed with multiple myeloma in 2018, and more than 30,800 patients died.10 Almost 40 percent of patients with multiple myeloma do not reach five-year survival.11

Although treatment may result in remission, unfortunately, patients will most likely relapse as there is currently no cure.12 Refractory multiple myeloma is when a patient’s disease is non-responsive or progresses within 60 days of their last therapy.13,14 Relapsed myeloma is when the disease has returned after a period of initial, partial or complete remission and does not meet the definition of being refractory.15 While some patients with multiple myeloma have no symptoms at all, most patients are diagnosed due to symptoms that can include bone problems, low blood counts, calcium elevation, kidney problems or infections.16 Patients who relapse after treatment with standard therapies, including PIs and IMiDs, have poor prognoses and few treatment options available.17

IMV Inc. to Present at the Bloom Burton & Co. Healthcare Investor Conference; Announces Update to Presentation at H.C. Wainwright Investor Conference

On April 4, 2019 IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company reported that IMV Chief Executive Officer, Frederic Ors will be making an investor presentation at the 2019 Bloom Burton & Co Healthcare Investor Conference, which will be held from April 30 to May 1, 2019 in Toronto, Ontario (Press release, IMV, APR 4, 2019, View Source [SID1234534999]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

IMV’s presentation details include:

Date: Wednesday, May 1, 2019
Time: 11:00 a.m. ET
Location: Metro Toronto Convention Centre, 255 Front St W, Toronto, ON
There will be a live webcast of IMV’s presentation accessible in the ‘Events, Webcasts & Presentations’ page of IMV’s website. The webcast will be archived for 90 days following the live presentation and a copy of the presentation will be available www.imv-inc.com.

April 9 H.C. Wainwright Investor Conference Presentation Update:

IMV also revealed a time change for its participation at the H.C. Wainwright Global Life Sciences Conference. IMV will now present at 1:10 p.m. local time. Full details include:

Venue: H.C. Wainwright Global Life Sciences Conference, being held April 7-9, 2019
Date: Tuesday, April 9, 2019
Time: 1:10 p.m. BST
Location: Stratton Suite, Grosvenor House, A JW Marriott Hotel, London, UK

Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2019 Financial Results on April 25, 2019

On April 4, 2019 Seattle Genetics, Inc. (Nasdaq: SGEN) reported that it will report its first quarter 2019 financial results on Thursday, April 25, 2019 after the close of financial markets (Press release, Seattle Genetics, APR 4, 2019, View Source [SID1234534998]). Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

LIVE access on Thursday, April 25, 2019

1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time

Telephone 877-260-1479 (domestic) or +1 334-323-0522 (international); conference ID 6169352
Webcast with slides available at www.seattlegenetics.com in the Investors section
REPLAY access

Telephone replay will be available beginning at approximately 4:30 p.m. PT on Thursday, April 25, 2019 through 5:00 p.m. PT on Monday, April 29, 2019 by calling 888-203-1112 (domestic) or +1 719-457-0820 (international); conference ID 6169352
Webcast replay will be available on the Seattle Genetics website at www.seattlegenetics.com in the Investors section